BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tonneijck L, Muskiet MHA, Blijdorp CJ, Smits MM, Twisk JW, Kramer MHH, Danser AHJ, Diamant M, Joles JA, Hoorn EJ, van Raalte DH. Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. Am J Physiol Renal Physiol 2019;316:F231-40. [PMID: 30353743 DOI: 10.1152/ajprenal.00432.2018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Shao S, Zhang X, Xu Q, Pan R, Chen Y. Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities. Pharmacology & Therapeutics 2022;239:108270. [DOI: 10.1016/j.pharmthera.2022.108270] [Reference Citation Analysis]
2 Cases A. Agonistas del receptor de péptido similar al glucagón tipo 1 (GLP-1) en el manejo del paciente con diabetes mellitus tipo 2. Una aproximación para el nefrólogo. Nefrología 2022. [DOI: 10.1016/j.nefro.2022.07.008] [Reference Citation Analysis]
3 Neumiller JJ, Alicic RZ, Tuttle KR. GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease. Kidney and Dialysis 2022;2:386-398. [DOI: 10.3390/kidneydial2030034] [Reference Citation Analysis]
4 Tye SC, de Vries ST, Mann JFE, Schechter M, Mosenzon O, Denig P, Heerspink HJL. Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers. Front Pharmacol 2022;13:786767. [DOI: 10.3389/fphar.2022.786767] [Reference Citation Analysis]
5 Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. Therapeutic peptides: current applications and future directions. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-00904-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 48] [Article Influence: 40.0] [Reference Citation Analysis]
6 Przezak A, Bielka W, Pawlik A. Incretins in the Therapy of Diabetic Kidney Disease. Int J Mol Sci 2021;22:12312. [PMID: 34830194 DOI: 10.3390/ijms222212312] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Natali A, Nesti L, Tricò D, Ferrannini E. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. Cardiovasc Diabetol 2021;20:196. [PMID: 34583699 DOI: 10.1186/s12933-021-01385-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
8 Andreasen CR, Andersen A, Knop FK, Vilsbøll T. Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. Diabetes Obes Metab 2021;23 Suppl 3:40-52. [PMID: 34519400 DOI: 10.1111/dom.14500] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Tricò D, Solini A. Glucagon-Like Peptide-1 Receptor Agonists-Use in Clinical Practice. Adv Chronic Kidney Dis 2021;28:328-36. [PMID: 34922689 DOI: 10.1053/j.ackd.2021.04.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Duan S, Lu F, Song D, Zhang C, Zhang B, Xing C, Yuan Y. Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease. Front Endocrinol (Lausanne) 2021;12:661185. [PMID: 34177803 DOI: 10.3389/fendo.2021.661185] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
11 Fan C, Asico LD, Villar VAM, Hunt J, Cuevas S, Armando I, Jose PA, Konkalmatt PR. NFAT5 Is Involved in GRP-Enhanced Secretion of GLP-1 by Sodium. Int J Mol Sci 2021;22:3951. [PMID: 33921209 DOI: 10.3390/ijms22083951] [Reference Citation Analysis]
12 Liu ZZ, Jose PA, Yang J, Zeng C. Importance of extracellular vesicles in hypertension. Exp Biol Med (Maywood) 2021;246:342-53. [PMID: 33517775 DOI: 10.1177/1535370220974600] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
13 Kawanami D, Takashi Y. GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms. Front Pharmacol 2020;11:967. [PMID: 32694999 DOI: 10.3389/fphar.2020.00967] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
14 Peter R, Bain SC. Safety of injectable semaglutide for type 2 diabetes. Expert Opinion on Drug Safety 2020;19:785-98. [DOI: 10.1080/14740338.2020.1772230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Yin WL, Bain SC, Min T. The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes. Diabetes Ther 2020;11:835-44. [PMID: 32185624 DOI: 10.1007/s13300-020-00798-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
16 Hviid AVR, Sørensen CM. Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation. American Journal of Physiology-Renal Physiology 2020;318:F443-54. [DOI: 10.1152/ajprenal.00280.2019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
17 Deeks E. Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use. Drugs Ther Perspect 2019;35:470-80. [DOI: 10.1007/s40267-019-00670-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]